Related Experiment Video

Updated: Mar 28, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.4K

The Nrf2/HO-1 Axis in Cancer Cell Growth and Chemoresistance

A L Furfaro1, N Traverso2, C Domenicotti2

  • 1Giannina Gaslini Institute, Via Gerolamo Gaslini 5, 16147 Genoa, Italy.

Oxidative Medicine and Cellular Longevity
|December 24, 2015
PubMed

Insights

The nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase 1 (HO-1) pathway regulates cellular defense against stress. Targeting this Nrf2/HO-1 mechanism offers a promising strategy to overcome cancer therapy resistance.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor that regulates cellular redox homeostasis.
  • Nrf2 activation leads to the expression of antioxidant and detoxifying genes, including heme oxygenase 1 (HO-1).
  • Elevated Nrf2 and HO-1 are observed in various cancers, correlating with poor prognosis and therapeutic resistance.

Purpose of the Study:

  • To review the Nrf2/HO-1 stress response pathway.
  • To explore its role in cancer progression and therapeutic resistance.
  • To highlight the potential of targeting Nrf2/HO-1 as an anticancer strategy.

Main Methods:

  • Literature review of studies on Nrf2, HO-1, and cancer.
  • Analysis of the molecular mechanisms underlying Nrf2/HO-1 activation in cancer.
  • Examination of preclinical and clinical data on targeting Nrf2/HO-1 in cancer therapy.

Main Results:

  • The Nrf2/HO-1 pathway is a key regulator of cellular defense against oxidative and electrophilic stress.
  • Upregulation of Nrf2 and HO-1 contributes to tumor progression, aggressiveness, and resistance to conventional therapies.
  • Inhibition of the Nrf2/HO-1 pathway shows potential in overcoming therapeutic resistance in various cancer types.

Conclusions:

  • The Nrf2/HO-1 pathway is a critical mediator of cancer cell survival and therapeutic resistance.
  • Targeting this pathway represents a promising approach for developing novel anticancer treatments.
  • Further research is warranted to fully elucidate the therapeutic potential of Nrf2/HO-1 inhibitors in oncology.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.7K
Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion09:23

Impedance-based Real-time Measurement of Cancer Cell Migration and Invasion

Published on: April 2, 2020

6.9K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.3K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.7K